

*Hong Kong Exchanges and Clearing Limited take no responsibility for the representation as to its accuracy or completeness whatsoever for any loss howsoever arising out of or in connection with any part of the contents of this announcement.*



**Hepalink**

**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**DATE OF BOARD MEETING**

The board of directors (the **Board**) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the **Company**), and together with its subsidiaries, the **Group** hereby announce that a meeting of the Board will be held on Friday, October 28, 2022 for the purpose of considering and approving the financial statements of the Group for the nine months ended September 30, 2022 and its publication.

By Order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, PRC  
October 14, 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*